John Soltys
Neurology · Mobile, ALNPI 1194221952
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 10.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,969, more than ten times the $136 reported in 2019.
Across 165 payments — averaging $24.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$404
- Eisai Inc.$333
- UCB, Inc.$313
- Novartis$301
- Amgen$213
- Jazz Pharmaceuticals Inc.$211
- plus $2K from 33 others
What the payments were for
- Speaking & faculty fees$1504%
- Food & beverage$3,82496%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $404 |
| Eisai Inc. | 17 | $333 |
| UCB, Inc. | 13 | $313 |
| Novartis | 13 | $301 |
| Amgen | 8 | $213 |
| Jazz Pharmaceuticals Inc. | 9 | $211 |
| Acadia Pharmaceuticals Inc | 9 | $206 |
| SK Life Science, Inc. | 6 | $190 |
| Acorda Therapeutics, Inc | 9 | $172 |
| Lundbeck LLC | 2 | $144 |
| Genentech USA, Inc. | 6 | $143 |
| Genentech, Inc. | 1 | $114 |
| AbbVie(2 entities) | 4 | $84 |
| Argenx US, Inc. | 3 | $83 |
| EMD Serono, Inc. | 4 | $83 |
| Biogen | 5 | $76 |
| Sanofi | 2 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Merz Pharmaceuticals, LLC | 2 | $63 |
| Supernus Pharmaceuticals, Inc. | 3 | $59 |
| Johnson & Johnson | 3 | $59 |
| Lilly USA, LLC | 4 | $58 |
| Neurocrine Biosciences, Inc. | 2 | $57 |
| Adamas Pharmaceuticals, Inc. | 3 | $56 |
| Upsher-smith Laboratories LLC | 3 | $54 |
| Tanabe Pharma America, Inc. | 3 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Grifols USA, LLC | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Neurelis, Inc. | 1 | $20 |
| Akcea Therapeutics, Inc. | 1 | $19 |
| TG Therapeutics, Inc. | 1 | $19 |
| Kedrion Biopharma, Inc. | 1 | $18 |
| CSL Behring | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NORTHERA$125
- OCREVUS$114
- Ocrevus Zunovo$114
How this compares
$3,974 in reported general payments places this provider in the 55th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Mobile
- Daniel DeesMobile$799K
- Hayden LongMobile$386K
- Charles MarkleMobile$212K
- William KilgoMobile$200K
- Bassam BassamMobile$197K
- Dean NaritokuMobile$160K
- Steve CordinaMobile$69K
- Thomas FosterMobile$51K
- Laura MintoMobile$33K
- Andrew ManleyMobile$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.